Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models
Technology in Cancer Research & Treatment · 2026-07 · 25
DOI: 10.1177/15330338261468414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 30.07.2026. Verfasst von Esther Frimpong und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA. Hauptthemen laut MEDLINE: Fluorouracil, Pancreatic Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS, National Institute of Health (NIH) National Institute on Minority Health and Health Disparities.
Abstract (Originalsprache)
Introduction
Dysregulated epidermal growth factor receptor (EGFR) signaling is a key mechanism driving cancer progression and metastasis. Owing to its frequent overexpression in pancreatic cancer (PCa), EGFR has become a desirable molecular target for targeted therapies. XYZ-I-73 (N-(5-fluoro-2-oxo-1-(tetrahydrofuran-2-yl)-1,2-dihydropyrimidin-4-yl) dodecanamide), a structural analog of 5-fluorouracil (5-FU), has been previously synthesized and shown to exhibit cytotoxicity against PCa cells.
Methods
XYZ-I-73 was entrapped in liposomes via thin-film hydration and subsequently conjugated to EGFR antibodies to produce an immunoliposome formulation- Ab-XYZ-I-73LnP (where ‘Ab’ denotes antibody-conjugated and ‘LnP’ denotes liposomal nanoparticle). In vitro efficacy was assessed by measuring cell viability and apoptosis in MiaPaCa-2 and PANC-1 cells, while pharmacokinetics and antitumor efficacy were determined in a cell line-derived xenograft (CDX) mouse model.
Results
Ab-XYZ-I-73LnP exhibited a mean particle size of 143nm ± 2.3, PDI (0.37), and zeta potential -46.2 ± 1.3mV. In MiaPaCa-2 cells, Ab-XYZ-I-73LnP showed remarkably higher cytotoxicity than 5-FU in both 2D (IC 50 = 2.5 ± 0.9μM vs 13.2 ± 1.1μM) and 3D cultures (IC 50 = 8.1 ± 1.1μM vs 26.7 ± 1.1 μM). Similarly, in PANC-1 cells, Ab-XYZ-I-73LnP showed lower IC 50 values compared to 5-FU;2D (IC 50 = 2.9 ±1.1 μM vs 20.4±1.2 μM), 3D (IC 50 = 12.9 ± 0.6μΜ vs 37.1±0.9 μM). Pharmacokinetic analysis revealed a prolonged half-life for Ab-XYZ-I-73LnP compared with free 5-FU (t1/2 = 1.62 ± 0.03 h vs 0.49 ± 0.01 h, p < 0.001). There was about a 2-fold increase in the area under the curve (AUC) for Ab-XYZ-I-73LnP compared to 5-FU (AUC= 0.32 ± 0.04µg/(L*hr) vs 0.15 ± 0.02µg/(L*hr), p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA.
- Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
- Department of Biobehavioral Nursing Science, College of Nursing, University of Florida, Gainesville, FL, USA.
ORCID-Profile: Esther Frimpong, Edward Agyare
Förderung
- NCI NIH HHS
- NIMHD NIH HHS
- National Institute of Health (NIH) National Institute on Minority Health and Health Disparities
- National Cancer Institute (NCI) of the National Institutes of Health
Zitieren
APA
Frimpong, E., Bulusu, R., Okoro, J., Zhu, X., Ablordeppey, J., Han, B., Yoon, S., & Agyare, E. (2026). Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261468414
Vancouver
Frimpong E, Bulusu R, Okoro J, Zhu X, Ablordeppey J, Han B, et al. Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261468414
BibTeX
@article{Frimpong2026,
author = {Frimpong, Esther and Bulusu, Raviteja and Okoro, Joy and Zhu, Xue and Ablordeppey, Joshua and Han, Bo and Yoon, Saunjoo and Agyare, Edward},
title = {Targeted Immunoliposomal Delivery of a 5-Fluorouracil Analog in EGFR-Expressing Pancreatic Cancer Models},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261468414}
}
EUVIMED